OCULAR IMPLANT WITH ANCHORING MECHANISM AND MULTIPLE OUTLETS

• US 20100087774A1
• Filed: 12/18/2008
• Published: 04/08/2010
• Est. Priority Date: 09/21/2002
• Status: Active Grant

• Current Assignee: Glaukos Corporation
• Original Assignee: Glaukos Corporation
• Inventors: Smedley, Gregory T., Haffner, David S., Tu, Hosheng, Burns, Thomas W.
• Granted Patent: US 8,007,459 B2
• Time in Patent Office: Days
• US Class Current: 604/8
• CPC Class Codes: A61F 9/00781 Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment drainage implants in general A61M27/002

Abstract

Devices and methods for treating ocular disorders are disclosed. One ocular implant, has a substantially straight, rigid, elongate body. The body has a self-trephinating distal portion that narrows toward a distal end, and at least one inlet that communicates with at least one inner lumen that communicates with a plurality of outlets. The lumen has a sufficient length to extend from an anterior chamber of an eye to a physiologic outflow pathway. An anchor member extends from the implant.

Claims

1. An ocular implant, comprising:

a substantially straight, rigid, elongate body, the body having a self-trephinating distal portion that narrows toward a distal end of the body, at least one inlet communicating with at least one inner lumen that communicates with a plurality of outlets, the lumen having a sufficient length to extend from an anterior chamber of an eye to a physiologic outflow pathway, and an anchor member extending from the body.

2. The implant of claim 1, further comprising means for regulating fluid flow through the lumen.

3. The implant of claim 2, further comprising a micro-pump communicating with said lumen.

4. The implant of claim 2, further comprising a pressure sensor coupled to the body.

5. The implant of claim 1 wherein the self-trephinating distal portion is sized and configured to penetrate a trabecular meshwork of the eye.

6. The implant of claim 1, wherein the self-trephinating distal portion is sized and configured to penetrate scleral tissue.

7. The implant of claim 1, wherein the self-trephinating distal portion is disposed distally of at least one outlet of said plurality of outlets.

8. The implant of claim 1, wherein at least one outlet of said plurality of outlets is arranged on said body so as to drain into the physiologic outflow pathway when the distal portion of the body is anchored in adjacent ocular tissue.

9. The implant of claim 8, wherein at least one outlet of said plurality of outlets is arranged on said body so as to drain into Schlemm'"'"'s canal when the distal portion of the body is anchored in adjacent ocular tissue.

10. The implant of claim 8, wherein at least one outlet of said plurality of outlets is arranged on said body so as to drain into aqueous collector channels when the distal portion of the body is anchored in adjacent ocular tissue.

11. The implant of claim 8, wherein at least one outlet of said plurality of outlets is arranged on said body so as to drain into aqueous veins when the distal portion of the body is anchored in adjacent ocular tissue.

12. The implant of claim 1, wherein said outlets are substantially longitudinally spaced along the body.

13. The implant of claim 1, wherein the anchor member is disposed proximally of the distal end of the body.

14. The implant of claim 1, wherein the anchor member is disposed distally of said at least one inlet.

15. The implant of claim 1, wherein the anchor member is disposed distally of at least one outlet of said plurality of outlets.

16. The implant of claim 1, wherein the elongate body has an outer surface of which at least a portion is porous.

17. The implant of claim 1, wherein the elongate body includes a coating which includes a bioactive agent.

18. The implant of claim 17, wherein the bioactive agent is selected from the group consisting of:

a vasodilating agent, an anti-glaucoma drug, or an anti-inflammatory drug.

19. The implant of claim 1, further comprising a biocompatible material in or on the implant.

20. The implant of claim 19, wherein the biocompatible material is selected from the group consisting of polyvinyl alcohol, polyvinyl pyrolidone, collagen, heparinized collagen, tetrafluoroethylene, fluorinated polymer, fluorinated elastomer, flexible fused silica, polyolefin, polyester, titanium, stainless steel, Nitinol, and polysilicon.

21. The implant of claim 19, wherein the biocompatible material has a surface coating selected from the group consisting of polytetrafluoroethylene (PTFE), polyimide, hydrogel, heparin, and a therapeutic drug.

22. The implant of claim 19, wherein the biocompatible material is capable of hydrating and expanding after implantation.

23. The implant of claim 1, wherein the implant comprises a therapeutic drug.

24. The implant of claim 23, wherein the implant comprises a polymer.

25. The implant of claim 23, wherein the implant includes a first portion and a second portion that is appended from the first portion, and wherein the first portion includes the lumen and the second portion carries the therapeutic drug.

26. The implant of claim 23, wherein at least a portion of the implant is coated with the therapeutic drug

27. The implant of claim 1, wherein the lumen has a sufficient length to extend from the anterior chamber of an eye to Schlemm'"'"'s canal.